Our tryst with Nucleic Acid Testing Dolly Daniel, Dept of Transfusion Medicine, CMC, Vellore.

Slides:



Advertisements
Similar presentations
Nick Curry, MD, MPH Infectious Diseases Prevention Section
Advertisements

High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.
HCV Assays: Impact on HCV Studies & Update on HCV blood bank protocol.
Presented by Cheri Booth, MPH MN Department of Health November 22, 2013.
A PROSPECTIVE STUDY OF POLYMERASE CHAIN REACTION TESTING ON POOLED PLASMA VS. INDIVIDUAL DONATION HIV P24 TESTING.
The Sense of Sensitivity I Dr. Matthias Gessner Plasma Control Europe/Plasma Analytics Baxter AG, Vienna.
Comparing the New EIAs with Old Standbys: Florida Bureau of Laboratories Verification Data HIV Diagnostics: New Developments and Challenges Feb. 28, 2005.
6/03/031 Hepatitis C –Update Laboratory Issues Hema Kapoor MD. SM Virology Section Manager Bureau of Laboratories Michigan Department of Community Health.
Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013.
Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:
1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.
The Safety of the Blood Supply
Molecular Diagnosis of Infectious Diseases. Why use a molecular test to diagnose an infectious disease? Need an accurate and timely diagnosis Important.
F. Kourgia, M. Vini, E. Zervou
Dengue Virus and Its Risk to the U.S. Blood Supply
Screening for HBsAg and Anti-HBc in North American Blood Donors John Saldanha, Roche Molecular Systems SoGAT XXI, May, 2009, Brussels, Belgium.
NAT Yield from Real Time Testing of Organ Donors for HIV-1 RNA and HCV RNA Safer Organs and No False Positive Results Claudia Chinchilla-Reyes, MB(ASCP)1,
HIV Testing CDC power point edited by M. Myers
Management of Risk and Blood Availability in Donor Populations with High Prevalence of Blood Borne Pathogens Ravi Reddy IBSF Meeting 20 March 2015.
Prevalence and risk relationships of tattoo, acupuncture and skin/body piercing histories among American Red Cross blood donors Sharyn Orton, MSPH, PhD.
PROFICIENCY TESTING OF IN-HOUSE NAT ASSAYS USED FOR BLOOD SCREENING XXI SoGAT International Working Group Meeting on the Standardization of NAT for the.
A Webinar Hosted by The National Harm Reduction Coalition The National Black Leadership Commission on AIDS The Coalition for Positive Health Empowerment.
E992750C 1 Replacement of HIV-1 p24 Antigen Screening with HIV-1 RNA Nucleic Acid Testing (NAT) for Whole Blood Donations S.L. Stramer, R.A. Porter, J.P.
Limitations of HBsAg testing in the screening of blood donors Wolfram H. Gerlich Institute of Medical Virology University Giessen, Germany SoGAT XVI Langen.
Lookback study for transfusion- related HBV infection in Japan Tokyo Metropolitan Red Cross Blood Center Masahiro Satake.
21 August 2015 Samreen Ijaz Virus Reference Department Health Protection Agency Indigenous HEV infection in the UK: a hazard for blood donation?
Pooled Source Plasma NAT for HIV-1 An Update from the Bayer HIV-1 IND Study Barbara Masecar Bayer Corporation Raleigh, NC Blood Products Advisory Committee.
BioLife Plasma Services Experience with HBV NAT Testing
TRANSFUSION SAFETY AN INTERNATIONAL FLAVOR. RISK DATA – U.S. Motor cycling 1:50 20 Cigarettes/d 1:200 Hit by car 1:20,000 BC pills 1:50,000 Earthquake.
And the order changeth …. Evolving protocols for TTI testing
Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.
PHS GUIDELINE FOR REDUCING TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS B VIRUS AND HEPATITIS C VIRUS THROUGH SOLID ORGAN TRANSPLANTATION ACOT.
FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.
IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.
Assessing the Response to Hepatitis B Immunizations in HIV-Positive Adults: Results from the 550 Clinic cohort study Camila Calderon 1, Anupama Raghuram.
CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.
21th VHPB meeting on “Prevention of viral hepatitis in Italy: lessons learnt and the way forward” Catania, 7-8 november 2002 RESIDUAL RISK OF TRANSFUSION-
Maria Rios, Ph.D. CBER/FDA Blood Products Advisory Committee May 1st, WNV Epidemiology & FDA’s Recommendations on the Use of NAT to Reduce the.
Recent, Five-Year HCV Sero-prevalence Trend Among Deceased Organ Donors in California Marek Nowicki 1, Dem Brucal 1, Claudia Chinchila 1, Steven Takemoto.
Retrospective and Prospective U.S. Donor MRV Surveillance and Transmission Studies Michael Busch, MD, PhD Blood Systems Research Institute Dept of Laboratory.
Persistent human erythrovirus infection in blood donors National Blood Service, UK Div. Transfusion Medicine, University of Cambridge, UK Public Health.
Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.
HIV diagnosis (general) ImmunoassaysNAT (PCR)
E001372A 1 ARC Experience with Indeterminate Blood Donors Susan L. Stramer, Ph.D. National Confirmatory Testing Laboratory American Red Cross.
The Use of Pooled Viral Load Testing to Identify Antiretroviral Treatment Failure Davey Smith 1, Susanne May 2, Josué Perez-Santiago 1, Matthew Strain.
NUCLEIC ACID AMPLIFICATION TECHNOLOGY HCV-RNA / HBV-DNA / HIV-RNA testing blood and blood components for transfusion Italian External Quality Assessment.
Management of Donors and Units that Test HBV NAT Positive: Current Considerations July 21, 2005 BPAC Meeting Robin Biswas, M.D. FDA/CBER/OBRR/DETTD.
Ro / BSD Hessen Institut für Transfusionsmedizin SoGAT XVII, Paris, Paris 2004 B19 Overview of Testing for Blood Banks W. Kurt Roth Red Cross Blood Transfusion.
Epidemiology of Transfusion Transmitted Disease Sharyn Orton, MT(ASCP)SBB, M.S.P.H, Ph.D. candidate Project Leader, Transmissible Diseases Department American.
E B—Anti-HBc Chart 1 10/2004 Anti-HBc Testing and Donor Reentry Results of a Pilot Study Susan L. Stramer, Ph.D. American Red Cross Blood Products.
February 24, 2016 | 1 Paul Strengers MD, FFPM Sanquin Blood Supply Amsterdam The Netherlands Risk assessment schemes: Impact of.
NAT as part of routine tests ? I disagree ! Dr Anjali Arun Mysore.
Evaluation of Hepatitis B surveillance system in Armenia, 2014 AUTHORS Karine Gevorgyan Lusine Paronyan Shushan Sargsyan Artavazd Vanyan NCDC, Armenia.
Ro / BSD Hessen Institut für Transfusionsmedizin SoGAT XVI, Langen 3 rd July 2003 Immediate Parvo B19 NAT testing of pooled donor samples: logistics and.
Holland Laboratory David A. Leiby, PhD Transmissible Diseases Department American Red Cross Holland Laboratory and Department of Microbiology and Tropical.
Relative Sensitivities of US Licensed NAT Assays for Detection of Viremia in Early HIV and HCV Infection MP Busch, SA Glynn, DJ Wright, D Hirschkorn, ME.
Serologic markers and molecular epidemiology of HBV from an HIV infected cohort from Cameroon Tshifhiwa Magoro 1, Emmaculate Nongpang 2, Lufuno Mavhandu.
Prevention of Viral Hepatitis B in Republic of Korea Ok Park, M.D., Ph.D., MPH Vaccine-Preventable Disease Control & National Immunization Program Korea.
Notified AIDS and HIV Infection Cases in the Seychelles: Epidemiological Trends Ministry of Health, SeychellesMinistry of Health, Seychelles –N. E. Udonwa.
Incorporation of NAT into supplemental testing of HCV and HIV seroreactive donors Michael P. Busch representing Blood Systems Research Institute Blood.
Abbott Laboratories ConfidentialPage 1 Update on West Nile Virus George J. Dawson, Ph.D. Abbott Laboratories.
Ann Intern Med. 2012;157(1): doi: / Figure Legend:
Donations After Reentry
How dangerous are Donor Travels?
Introduction Results Conclusions Methods
NUCLEIC ACID AMPLIFICATION TESTING DETECTS HIV TRANSMISSION RISK IN SEROLOGICALLY- TESTED BLOOD DONOR UNITS. |Presented by Miss Shemau Muniru| Authors:
By: Antehun Alemayehu (M.Sc)
INTRODUCTION The International Society of Blood Transfusion (ISBT) recognizes more than 300 Red Blood Cell (RBC) antigens that belong to 35 different recognized.
© The Author(s) Published by Science and Education Publishing.
Presentation transcript:

Our tryst with Nucleic Acid Testing Dolly Daniel, Dept of Transfusion Medicine, CMC, Vellore

CMC, Vellore A Large mission hospital > 100 years old Over 2200 IP beds Over 6000 OP a day About units of blood / components- annual usage Strong component of education / service and research

BB- Id Testing Only Hepatitis B testing 1988 – HIV 1997 – HCV All testing initiated before testing became mandatory for licensing

Why NAT at CMC??? Donor spread Seropositivity Anecdotal incidents of seroconversion

The American Red Cross accepts blood donations only from volunteer donors. Among Red Cross donors in a given year, 19 percent donate occasionally, 31 percent are first-time donors, and 50 percent are regular, loyal donors.

Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid– Amplification Testing -NEJM ,164,054 units screened Negative on serology 12 positive for HIV-1 RNA (1 in 3.1 million) (2 of which were detected by HIV-1 p24 antigen) 170 positive for HCV RNA ( 1 in 230,000) The respective rates of positive HCV and HIV-1 nucleic acid– amplification tests were 3.3 and 4.1 times as high among first-time donors as among donors who gave blood repeatedly Follow-up studies of 67 HCV RNA–positive donors demonstrated that seroconversion occurred a median of 35 days after the index donation Three cases of long-term immunologically silent HCV infection were documented

Donor Profile Almost 70% are replacement donors In the West – 100% Voluntary Repeat donors? ?? Process of deferral / self deferral / temporary / permanent and attitudes - very different

Linear Trend line

Issues Patient Safety (Staff requesting better ID screens) Quality of blood products One product being issued to even 5 babies

. Eskimo: "If I did not know about God and sin, would I go to hell?" Priest: "No, not if you did not know." Eskimo: "Then why did you tell me?"Eskimo: "Then why did you tell me?"” Annie Dillard

The Indian Experience – IJMR Feb 2008

India and NAT Total no of samples: Replacement donors : 8999 Voluntary donors : 3225 Seropositivity % – HIV, 0.33% HCV, 1.12% HBV

Seronegative but NAT positive Yield - 8 / Overall positivity – 1/1528 donations HIV - 1/ HCV / HIV 1 co infection- 1/12224 HBV – 6/12224

NAT testing would prevent 3272 infectious transfusions 818 HIV infected units 409 HCV infected units & 2454 HBV infected units from being transfused. If components are being processed – then double or triple these numbers

Translation to the CMC scenario Our donor distribution is very similar We have about donors bled each year X 2 / 3 components Approx 1/1500 transfusions infected Therefore about 35 of our patients are being infected annually by TTIs. (calculation of 2 components per donation)

CMC Stats IJMR seropos CMC seropos IJMR (NAT yield ) CMC Projected HIV 32 (0.26%) 70 (0.17%) 2 NAT pos /32 seropos 12 (4x3) HBV 137 (1.12%) 488 ( 2.19%) 6 NAT pos /137 seropos 54 (18x3) HCV 40 (0.33%) 214 (0.96%) 1 NAT pos /40 seropos 15 (5x3)

Institution 3 years …….. Justified Negotiated Presentations to clinicians

The process Challenges Infrastructure and space requirements Cost impact

Assessments Projected numbers of possible yields Health technology assessment Permitted on a trial basis

"The trouble with jogging is that by the time you realize you're not in shape for it, it's too far to walk back." Franklin Jones

The interim we waited….. No substitute for repeat voluntary donors No substitute for the practice of appropriate and rational use of blood

The Numbers Total Donors Screened – Sero positives – 594 Sero Negative

Seropositives HIV – 51 ( 0.18%) HBV – 364 ( 1.30%) HCV –179 ( 0.67%) Seropositive NAT Negative HIV – 37 HCV – 166 HBV - 49

Total seronegative units NAT positive – 68 Positive on repeat testing and discriminatory assays - 28 (0.105%) 1 per 950 donors approx)

Spread of positives HBV 22 HCV 3 HBV & HCV 2 HIV 1

One time positives and their significance ? ? False positives ? Low viral loads – Poissonian distribution Follow up recommended ?

Is it worth continuing? Cost per prevented infection At the cost of what?

He who sleeps on the floor will not fall off the bed. Robert Gronock..

In the context of transfusion services Has to be driven in the context of each individual institution Accessibility missing …… NAT available Basics of safe donor recruitment and appropriate use of blood and components

To conclude NAT seems to have worked for us… The confirmation of NAT yields is worth following up Working up samples which are one time NAT reactive – a must

Above all Each institution needs to thrash out the issue for itself Imperative that simple and safety measures like repeat voluntary donor recruitment and rational use of blood be focused upon alongside